FRANKFURT (Reuters) - German drugmaker Merck said on Wednesday it had agreed to supply its potential COVID-19 drug Rebif to European Union countries should orders be placed for the treatment.
The comment followed a Reuters report earlier on Wednesday about a deal reached by the EU Commission and Merck for the supply of Rebif. A similar deal was struck with Roche about possible COVID-19 treatment RoActemra.
“Merck has been asked by the European Commission to be prepared to supply one of its medicines, Rebif (Interferon beta-1a), to EU countries upon request if and when the indication for COVID-19 treatment is adjudicated,” the company said in a statement to Reuters.
Rebif is currently used for the treatment of relapsing multiple sclerosis and is being tested as a possible therapy for COVID-19 patients.
Reporting by Patricia Weiss in Frankfurt; writing by Francesco Guarasco. Editing by Jane Merriman
Our Standards: The Thomson Reuters Trust Principles.